KPF
ARLZ

K2 Principal Fund’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

K2 Principal Fund’s Portfolio ARLZ Stock Details ARLZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-29,060
Closed -$62K – 470
2017
Q1 		$62K Sell
29,060
-69,518
-71% -$261K 0.01% 290
2016
Q4 		$435K Buy
98,578
+80,045
+432% +$380K 0.04% 208
2016
Q3 		$90K Buy
+18,533
New +$84.5K 0.01% 266

Other funds holding ARLZ

PCM
PAR Capital Management Boston, Massachusetts $3.45B AUM 28.5% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return

K2 Principal Fund's ARLZ Position: Q2 2017 in Review

K2 Principal Fund sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q2 2017, closing a stake of 29,060 shares — an estimated $62K sold.

K2 Principal Fund first reported a position in ARLZ in Q3 2016 and held it in 3 quarters. The position peaked at $435K in Q4 2016. 72 funds tracked by Wall St. Rank hold ARLZ as of Q2 2017.

  • K2 Principal Fund reported no remaining Aralez Pharmaceuticals Inc. position as of Q2 2017 after selling out during the quarter.
  • K2 Principal Fund sold 29,060 Aralez Pharmaceuticals Inc. shares in Q2 2017, an estimated $62K.
  • K2 Principal Fund first reported a position in Aralez Pharmaceuticals Inc. in Q3 2016 and held it in 3 quarters.
  • K2 Principal Fund's Aralez Pharmaceuticals Inc. position peaked at $435K in Q4 2016.
  • 72 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q2 2017.

Based on K2 Principal Fund's 13F filing for Q2 2017, filed 11 Aug 2017.